Mainz Biomed (MYNZ) Prices 1.5M Share Follow-on Offering at $15/sh

January 26, 2022 5:50 AM EST

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the pricing of its underwritten public follow-on offering (the “Follow-on Offering”) of 1,500,000 ordinary shares at a public offering price of US$15.00 per ordinary share (the “Offering Price”), for gross proceeds of $22,500,000.

The Follow-on Offering is being made pursuant to a registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission (“SEC”). The Follow-on Offering is expected to close on January 28, 2022, subject to the satisfaction of customary closing conditions. In connection with the Follow-on Offering, Mainz Biomed has granted the underwriter the option to purchase up to 225,000 additional ordinary shares at the Offering Price to cover over-allotments, if any. All shares are being offered by Mainz Biomed.

Boustead Securities, LLC is acting as the sole underwriter for the offering. Ortoli Rosenstadt LLP served as counsel to Mainz Biomed. Sichenzia, Ross and Ference LLP served as counsel to the underwriter.

The offering is being made only by means of a prospectus. A copy of the final prospectus related to the offering may be obtained, when available, from Boustead Securities, LLC, via email: [email protected] or by calling +1 (949) 502-4408 or standard mail at Boustead Securities, LLC, Attn: Equity Capital Markets, 6 Venture, Suite 395, Irvine, CA 92618, USA. In addition, a copy of the final prospectus, when available, relating to the offering may be obtained via the SEC’s website at www.sec.gov.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Equity Offerings

Related Entities

FDA, F1